Previous 10 | Next 10 |
AVXL reported positive topline data from their trial for Rett syndrome in adults on Feb 1, 2022. However, the results were met with much skepticism or cynicism, due to changes to the trial's endpoints, registered on the clinicaltrials.gov site that was submitted on Jan 18. AVXL CE...
NEW YORK, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diso...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of Anavex stockholders. Our investigation concerns ...
MDJM (NASDAQ:MDJH) +64%. The OLB Group OLB +25% reports $1.35B in transaction value post CBD Merchants acquisition. Advanced Micro Devices AMD +13% on Q4 results. Xilinx (NASDAQ:XLNX) +12%. Capri Holdings CPRI +12% on Q3 results. IceCure Medical (NASDAQ:ICCM) +11%. Arrival...
Positive results reported from the phase 3 AVATAR study using Anavex 2-73 for the treatment of adult females with Rett Syndrome; Primary endpoint of RSBQ AUC met with statistical significance. Positive results from phase 3 AVATAR study, along with prior positive results from phase 2, ...
Gainers: Dave (NASDAQ:DAVE) +37%. Windtree Therapeutics (NASDAQ:WINT) +24%. BioRestorative Therapies (NASDAQ:BRTX) +19%. Creative Realities (NASDAQ:CREX) +19%. Biofrontera (NASDAQ:BFRI) +18%. voxeljet (NASDAQ:VJET) +18%. Immunic (NASDAQ:IMUX) +18%. Digihost Technology (NASDAQ:DGHI) +17%. Hype...
Shares of Anavex Life Sciences (AVXL -15.5%) are under pressure even though the company reported earlier this morning that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndome met primary and secondary endpoints. Since a news release came out this morning, several people on social me...
Gainers: Biofrontera (NASDAQ:BFRI) +14%. Synaptogenix (NASDAQ:SNPX) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Immunic (NASDAQ:IMUX) +10%. Oncternal Therapeutics (NASDAQ:ONCT) +10%. Losers: Sio Gene Therapies (NASDAQ:SIOX) -19%. Anavex Life Sciences (NASDAQ:A...
Announcing topline data from its AVATAR trial for ANAVEX2-73 (blarcamesine), Anavex Life Sciences (NASDAQ:AVXL) said that the Phase 3 study met primary and secondary efficacy endpoints in adult females with Rett syndrome. Anavex (AVXL) shares are trading ~1.8% lower in the pre-marke...
Primary and all secondary efficacy and safety endpoints met, with consistent improvements in RSBQ AUC (p = 0.037), ADAMS (p = 0.010) and CGI-I (p = 0.037) response Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome sym...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...